Bulk Manufacturer of Controlled Substances Application: Halo Pharmaceutical, Inc., 43571 [2017-19834]
Download as PDF
<![CDATA[
43571
Federal Register / Vol. 82, No. 179 / Monday, September 18, 2017 / Notices
The company plans to manufacture
bulk active pharmaceutical ingredients
(APIs) for distribution to its customers.
Dated: September 13, 2017
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–19786 Filed 9–15–17; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
Marihuana .......................
Phenylacetone ................
Coca Leaves ..................
Opium, raw .....................
Poppy Straw Concentrate.
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Specgx LLC
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before October 18, 2017. Such
persons may also file a written request
for a hearing on the application
pursuant to 21 CFR 1301.43 on or before
October 18, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
sradovich on DSKBBY8HB2PROD with NOTICES
DATES:
VerDate Sep<11>2014
16:54 Sep 15, 2017
Drug
code
Controlled substance
DEPARTMENT OF JUSTICE
ACTION:
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on August
9, 2017, Specgx LLC, 3600 North
Second Street, Saint Louis, Missouri
63147 applied to be registered as an
importer of the following basic classes
of controlled substances:
Jkt 241001
Schedule
7360
8501
9040
9600
9670
I
II
II
II
II
The company plans to import the
listed controlled substances to bulk
manufacture into Active Pharmaceutical
Ingredients for distribution to its
customers. In reference to drug code
7360 (marihuana) the company plans to
import a synthetic cannabidiol. No other
activity for this drug code is authorized
for this registration. Placement of these
drug codes onto the company’s
registration does not translate into
automatic approval of subsequent
permit applications to import controlled
substances. Approval of permit
applications will occur only when the
registrant’s business activity is
consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization
will not extend to the import of FDA
approved or non-approved finished
dosage forms for commercial sale.
Dated: September 11, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–19784 Filed 9–15–17; 8:45 am]
BILLING CODE 4410–09–P
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on July 11,
2017, Halo Pharmaceutical, Inc., 30
North Jefferson Road, Whippany, New
Jersey 07981 applied to be registered as
a bulk manufacturer the following basic
classes of controlled substances:
Controlled substance
Dihydromorphine ..........
Hydromorphone ............
Drug
code
9145
9150
Schedule
I
II
The company plans to manufacture
Hydromorphone (9150) for distribution
to its customers. Dihydromorphine
(9145) is an intermediate in the
manufacture of Hydromorphone and is
not for commercial distribution.
Dated: September 11, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–19834 Filed 9–15–17; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
[Docket No. DEA–392]
Drug Enforcement Administration
Bulk Manufacturer of Controlled
Substances Application: Halo
Pharmaceutical, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before November 17, 2017.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
DATES:
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Unither Manufacturing
LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before October 18, 2017. Such
persons may also file a written request
DATES:
E:\FR\FM\18SEN1.SGM
18SEN1
]]>Agencies
[Federal Register Volume 82, Number 179 (Monday, September 18, 2017)]
[Notices]
[Page 43571]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19834]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Halo
Pharmaceutical, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before November 17, 2017.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DRW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on July
11, 2017, Halo Pharmaceutical, Inc., 30 North Jefferson Road, Whippany,
New Jersey 07981 applied to be registered as a bulk manufacturer the
following basic classes of controlled substances:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Dihydromorphine........................ 9145 I
Hydromorphone.......................... 9150 II
------------------------------------------------------------------------
The company plans to manufacture Hydromorphone (9150) for
distribution to its customers. Dihydromorphine (9145) is an
intermediate in the manufacture of Hydromorphone and is not for
commercial distribution.
Dated: September 11, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017-19834 Filed 9-15-17; 8:45 am]
BILLING CODE P
